Company Overview
Immatics N.V. operates as a clinical-stage biopharmaceutical entity dedicated to the research and development of potential T cell redirecting immunotherapies designed for the treatment of cancer within the United States. This specialized focus places the company squarely within the healthcare sector, specifically the biotechnology industry, where it pursues the advancement of targeted immunotherapies with an emphasis on treating solid tumors through two distinct approaches. The organization currently employs 589 individuals to support its extensive research and development pipeline, reflecting the significant human capital required for clinical-stage operations. With a market capitalization of $1.23B and trailing twelve-month revenue of $48.27M, Immatics N.V. represents a mid-cap biotechnology enterprise, a position that suggests a company with substantial resources yet still navigating the high-risk, high-reward landscape of bringing novel cancer therapies to market.
Financial Health
The company reported a revenue of $48.27M over the trailing twelve months, yet simultaneously recorded a net income of $-196,447,008 and an EBITDA of $-172,875,008, indicating a profound structural cost burden where expenses significantly outpace revenue generation. The free cash flow stands at $-128,190,248, which highlights a heavy burn rate typical for clinical-stage biotechs but underscores a critical need for capital management to maintain financial flexibility during the development phase. Analysis of the three key margins reveals a gross margin of -280.9%, an operating margin of -196.8%, and a profit margin of 0.0%, all of which signal that the company is not currently profitable and is operating at a loss across all standard profitability metrics. Despite the negative income, the balance sheet maintains a cash reserve of $469.34M against a debt load of only $15.63M, suggesting a leveraged but cash-rich position where liquidity far exceeds obligations. The debt-to-equity ratio is recorded at 3.23, while the current ratio sits at an exceptionally high 11.72, indicating robust short-term liquidity and a strong ability to meet immediate financial obligations. Furthermore, the return on equity is -37.1% and the return on assets is -18.1%, metrics that reveal that management is currently utilizing shareholder and asset bases to generate negative returns rather than positive value creation.
Valuation Assessment
Valuation multiples for Immatics N.V. show a trailing P/E ratio of N/A and a forward P/E of -5.21, implying that earnings are currently negative and that any forward-looking P/E calculation assumes a trajectory that has not yet materialized in actual profit. The price-to-book ratio is 2.20, which indicates that the market is currently pricing the company at more than double its book value, reflecting a premium assigned to its intangible assets and potential pipeline rather than current earnings power. Alternative valuation metrics include a price-to-sales ratio of 25.56 and an EV/EBITDA of -4.51, figures that suggest the market is valuing the company primarily on revenue generation and future potential rather than current profitability or cash flow generation. In terms of trading range, the stock has a 52-week high of $12.41 and a 52-week low of $3.30, with the current price trading significantly below the 52-week high, reflecting the volatility and risk premium inherent in the biotechnology sector. The beta is 1.35, which means the stock's price volatility is 35% higher than the broader market, indicating that the stock will likely experience amplified swings relative to market movements.
Growth & Income
Revenue growth year-over-year is recorded at -64.9%, while earnings growth is listed as N/A, illustrating a scenario where the company is contracting in revenue rather than expanding, a common challenge for clinical-stage firms facing pipeline delays or market shifts. Because the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, it follows a model of reinvesting all available earnings and cash reserves back into research and development rather than distributing income to shareholders. The absence of dividend payments confirms that Immatics N.V. prioritizes capital allocation toward advancing its T cell redirecting immunotherapies over providing current income to investors. Overall, the growth and income profile is characterized by negative revenue momentum and a complete reliance on external financing or cash reserves to fund operations, as the company has no mechanism for generating shareholder income through dividends.